Zhao Heming Hannah, Wilhelm Scott Michael
University Hospitals Cleveland Medical Center, Cleveland, OH.
University Hospitals Cleveland Medical Center, Cleveland, OH.
Surgery. 2025 Jan;177:108827. doi: 10.1016/j.surg.2024.05.049. Epub 2024 Oct 9.
Well-differentiated thyroid cancer includes papillary thyroid, follicular thyroid, and Hurthle cell cancers, comprising approximately 95% of all thyroid cancers in the United States. This study aims to understand well-differentiated thyroid cancer in the Asian population.
We analyzed the National Cancer Database from 2004 to 2019, categorizing the Asian population based on the available ethnicities. Multivariable logistic regression assessed the associations between ethnic groups and disease stage/nodal positivity. Survival outcomes were evaluated using the Kaplan-Meier and Cox regression analyses.
A total of 364,604 adult patients were analyzed. The Asian ethnic groups included were Chinese (n = 3,851), Japanese (n = 740), Filipino (n = 3,466), Korean (n = 1,567), Vietnamese (n = 1,517), Laotian (n = 101), Hmong (n = 50), Kampuchean (n = 166), Thai (n = 160), Asian Indian (n = 1,526), Pakistani (n = 167), and Pacific Islander (n = 446). Japanese, Korean, and Laotian had higher percentages of stage III disease, whereas Japanese, Filipino, and Laotian had higher proportions of stage IV disease than the White population. Most Asian ethnicities had more patients with metastasis than the White population. Korean patients exhibited a 15% increased likelihood of metastasis (odds ratio: 1.15, confidence interval: 1.03-1.28, P < .05), whereas Pakistani patients were at 40% higher odds (odds ratio: 1.40, confidence interval: 1.03-1.91, P < .05), compared with White patients. Japanese, Laotian, and Kampuchean patients experienced worse 5- and 10-year overall survival than the White population.
Our study revealed substantial variation in well-differentiated thyroid cancer characteristics and outcomes among diverse Asian ethnicities. This challenges the notion of Asians as a homogeneous population, emphasizing tailored disease management for this heterogeneous group of patients.
高分化甲状腺癌包括乳头状甲状腺癌、滤泡状甲状腺癌和许特莱细胞癌,约占美国所有甲状腺癌的95%。本研究旨在了解亚洲人群中的高分化甲状腺癌。
我们分析了2004年至2019年的国家癌症数据库,根据现有的种族对亚洲人群进行分类。多变量逻辑回归评估了种族与疾病分期/淋巴结阳性之间的关联。使用Kaplan-Meier和Cox回归分析评估生存结果。
共分析了364,604例成年患者。纳入的亚洲种族包括中国人(n = 3,851)、日本人(n = 740)、菲律宾人(n = 3,466)、韩国人(n = 1,567)、越南人(n = 1,517)、老挝人(n = 101)、苗族人(n = 50)、柬埔寨人(n = 166)、泰国人(n = 160)、亚洲印度人(n = 1,526)、巴基斯坦人(n = 167)和太平洋岛民(n = 446)。与白人相比,日本人、韩国人和老挝人III期疾病的比例更高,而日本人、菲律宾人和老挝人IV期疾病的比例更高。大多数亚洲种族发生转移的患者比白人多。与白人患者相比,韩国患者发生转移的可能性增加了15%(优势比:1.15,置信区间:1.03 - 1.28,P < 0.05),而巴基斯坦患者的优势比高40%(优势比:1.40,置信区间:1.03 - 1.91,P < 0.05)。与白人相比,日本人、老挝人和柬埔寨患者的5年和10年总生存率更差。
我们的研究揭示了不同亚洲种族在高分化甲状腺癌特征和结果方面存在显著差异。这挑战了将亚洲人视为同质人群的观念,强调针对这一异质患者群体进行个性化疾病管理。